Previous 10 | Next 10 |
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS) , being ...
2023-10-02 09:34:12 ET More on Blackstone, Amicus, etc. Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter Blackstone Surges From A Solid Foundation (Technical Analysis) Blackstone Stock: 3 Reasons To Sell It Right Now Blac...
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focus...
2023-09-29 11:00:14 ET Summary Shares of Amicus Therapeutics declined after FDA approval of Pombiliti and Opfolda for late-onset Pompe disease due to a worse-than-expected label. The label states that only patients not improving on existing treatments are eligible for Pombiliti an...
2023-09-28 11:27:36 ET More on Amicus Therapeutics Amicus closes up 5% as it expects approval of Pompe disease therapy Amicus: Holding Until AT-GAA U.S. Approval Amicus Therapeutics: U.K. Approval Expands Global Reach Amicus closes up 5% as it expects app...
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today ...
2023-09-27 16:35:27 ET More on Amicus Therapeutics Amicus: Holding Until AT-GAA U.S. Approval Amicus Therapeutics: U.K. Approval Expands Global Reach Amicus announces U.K. approval and launch of Pompe disease therapy Amicus Therapeutics reports mixed Q2 earni...
2023-09-06 08:12:04 ET Summary Protalix BioTherapeutics reported Q2 2023 revenues of $35.08 million, a 300.72% YoY increase, beating Wall Street estimates. The US FDA approved PLX's Elfabrio for the treatment of Fabry disease in adults, expanding its commercialization target. ...
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 21 st Annual Global Healthcare Conference in New York, NY o...
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 , bein...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2024. Par...
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...